Immunohistochemistry in gastroenterohepatopancreatobiliary epithelial neoplasia: Practical applications, pitfalls, and emerging markers

Surgical Pathology Clinics

Volumn 6, Issue 3, 2013, Pages 567-609

  Bellizzi, Andrew M ^a  

^a UNIVERSITY OF IOWA HOSPITALS AND CLINICS   (United States)

Author keywords

Differential diagnosis; DNA mismatch repair; HER2; Immunohistochemistry; P53; Predictive markers; Site of origin; Tumor classification

Indexed keywords

CISPLATIN; FLUOROPYRIMIDINE; MUCIN 1; MUCIN 2; MUCIN 5AC; MUCIN 6; PROSTATE SPECIFIC ANTIGEN; PROTEIN MSH2; PROTEIN MSH6; PROTEIN P53; SYNAPTOPHYSIN; THYROID TRANSCRIPTION FACTOR 1; TRANSCRIPTION FACTOR CDX2; TRANSCRIPTION FACTOR SOX2; TRASTUZUMAB;

ADJUVANT THERAPY; APOPTOSIS; APPENDIX CARCINOMA; BARRETT ESOPHAGUS; BILE DUCT CARCINOMA; BREAST CANCER; COLON POLYP; COLORECTAL CANCER; COLORECTAL TUMOR; CONFORMATIONAL TRANSITION; CROSS REACTION; DIAGNOSTIC ERROR; DIAGNOSTIC TEST ACCURACY STUDY; DIFFERENTIAL DIAGNOSIS; DNA DAMAGE; DYSPLASIA; ENDOMETRIUM CARCINOMA; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; ESOPHAGUS CARCINOMA; FALSE POSITIVE RESULT; FLUORESCENCE IN SITU HYBRIDIZATION; FRAMESHIFT MUTATION; GASTRECTOMY; GASTROESOPHAGEAL REFLUX; GENE DELETION; GENE EXPRESSION PROFILING; GENOMIC INSTABILITY; HEPATOBLASTOMA; HEREDITARY NONPOLYPOSIS COLORECTAL CANCER; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IMMUNOPHENOTYPING; LIVER CELL CARCINOMA; LUNG ADENOCARCINOMA; LUNG SMALL CELL CANCER; MEDULLARY CARCINOMA; METASTASIS; MISMATCH REPAIR; MISSENSE MUTATION; MUTATIONAL ANALYSIS; NEUROENDOCRINE TUMOR; NODULAR HYPERPLASIA; PANCREAS ADENOCARCINOMA; PANCREATIC NEUROENDOCRINE TUMOR; PHENOTYPE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; RECTUM ADENOMA; REVIEW; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; STOMACH ADENOCARCINOMA; STOMACH CANCER; WILD TYPE; YOLK SAC TUMOR;

EID: 84883778410     PISSN: 18759181     EISSN: 18759157     Source Type: Journal    
DOI: 10.1016/j.path.2013.06.003     Document Type: Review

References (101)

1. Bhat S., Coleman H.G., Yousef F., et al. Risk of malignant progression in Barrett's esophagus patients: results from a large population-based study. JNatl Cancer Inst 2011, 103(13):1049-1057.
2. Hvid-Jensen F., Pedersen L., Drewes A.M., et al. Incidence of adenocarcinoma among patients with Barrett's esophagus. NEngl J Med 2011, 365(15):1375-1383.
3. Montgomery E., Bronner M.P., Goldblum J.R., et al. Reproducibility of the diagnosis of dysplasia in Barrett esophagus: a reaffirmation. Hum Pathol 2001, 32(4):368-378.
4. Kaye P.V., Haider S.A., Ilyas M., et al. Barrett's dysplasia and the Vienna classification: reproducibility, prediction of progression and impact of consensus reporting and p53 immunohistochemistry. Histopathology 2009, 54(6):699-712.
5. Weston A.P., Banerjee S.K., Sharma P., et al. p53 protein overexpression in low grade dysplasia (LGD) in Barrett's esophagus: immunohistochemical marker predictive of progression. Am J Gastroenterol 2001, 96(5):1355-1362.
6. Skacel M., Petras R.E., Rybicki L.A., et al. p53 expression in low grade dysplasia in Barrett's esophagus: correlation with interobserver agreement and disease progression. Am J Gastroenterol 2002, 97(10):2508-2513.
7. Kastelein F., Biermann K., Steyerberg E.W., et al. Aberrant p53 protein expression is associated with an increased risk of neoplastic progression in patients with Barrett's oesophagus. Gut 2012, [Epub ahead of print].
8. Nigro J.M., Baker S.J., Preisinger A.C., et al. Mutations in the p53 gene occur in diverse human tumour types. Nature 1989, 342(6250):705-708.
9. Finlay C.A., Hinds P.W., Tan T.H., et al. Activating mutations for transformation by p53 produce a gene product that forms an hsc70-p53 complex with an altered half-life. Mol Cell Biol 1988, 8(2):531-539.
10. Baas I.O., Mulder J.W., Offerhaus G.J., et al. An evaluation of six antibodies for immunohistochemistry of mutant p53 gene product in archival colorectal neoplasms. JPathol 1994, 172(1):5-12.
11. Kaye P.V., Haider S.A., James P.D., et al. Novel staining pattern of p53 in Barrett's dysplasia-the absent pattern. Histopathology 2010, 57(6):933-935.
12. Huang Q., Wu H., Nie L., et al. Primary high-grade neuroendocrine carcinoma of the esophagus: a clinicopathologic and immunohistochemical study of 42 resection cases. Am J Surg Pathol 2013, 37(4):467-483.
13. Long K.B., Hornick J.L. SOX2 is highly expressed in squamous cell carcinomas of the gastrointestinal tract. Hum Pathol 2009, 40(12):1768-1773.
14. DiMaio M.A., Kwok S., Montgomery K.D., et al. Immunohistochemical panel for distinguishing esophageal adenocarcinoma from squamous cell carcinoma: a combination of p63, cytokeratin 5/6, MUC5AC, and anterior gradient homolog 2 allows optimal subtyping. Hum Pathol 2012, 43(11):1799-1807.
15. Borrisholt M., Nielsen S., Vyberg M. Demonstration of CDX2 is highly antibody dependant. Appl Immunohistochem Mol Morphol 2013, 21(1):64-72.
16. Bellizzi A.M. Assigning site of origin in metastatic neuroendocrine neoplasms: a clinically significant application of diagnostic immunohistochemistry. Adv Anat Pathol 2013, 20(5):285-314.
17. Myklebust A.T., Beiske K., Pharo A., et al. Selection of anti-SCLC antibodies for diagnosis of bone marrow metastasis. Br J Cancer Suppl 1991, 14:49-53.
18. Pai R.K., West R.B. MOC-31 exhibits superior reactivity compared with Ber-EP4 in invasive lobular and ductal carcinoma of the breast: a tissue microarray study. Appl Immunohistochem Mol Morphol 2009, 17(3):202-206.
19. Lauwers G.Y., Carneiro F., Graham D.Y., et al. Gastric carcinoma. World Health Organization Classification of Tumours WHO Classification of Tumours of the Digestive System 2010, 48-58. IARC, Lyon. 4th edition. F.T. Bosman, F. Carneiro, R.H. Hruban (Eds.).
20. Chu P.G., Weiss L.M. Immunohistochemical characterization of signet-ring cell carcinomas of the stomach, breast, and colon. Am J Clin Pathol 2004, 121(6):884-892.
21. O'Connell F.P., Wang H.H., Odze R.D. Utility of immunohistochemistry in distinguishing primary adenocarcinomas from metastatic breast carcinomas in the gastrointestinal tract. Arch Pathol Lab Med 2005, 129(3):338-347.
22. Nguyen M.D., Plasil B., Wen P., et al. Mucin profiles in signet-ring cell carcinoma. Arch Pathol Lab Med 2006, 130(6):799-804.
23. Wei S., Said-Al-Naief N., Hameed O. Estrogen and progesterone receptor expression is not always specific for mammary and gynecologic carcinomas: a tissue microarray and pooled literature review study. Appl Immunohistochem Mol Morphol 2009, 17(5):393-402.
24. Gomez-Fernandez C., Mejias A., Walker G., et al. Immunohistochemical expression of estrogen receptor in adenocarcinomas of the lung: the antibody factor. Appl Immunohistochem Mol Morphol 2010, 18(2):137-141.
25. Bellizzi AM. Contributions of molecular analysis to the diagnosis and treatment of gastrointestinal neoplasms. Semin Diagn Pathol, in press.
26. Bang Y.J., Van Cutsem E., Feyereislova A., et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 2010, 376(9742):687-697.
27. NCCN clinical practice guidelines in oncology. Esophageal and esophagogastric junction cancers. 2012 [7/12/12]; Version 2.2012. Available at: Accessed July 12, 2012. http://www.nccn.org/professionals/physician_gls/pdf/esophageal.pdf.
28. Hofmann M., Stoss O., Shi D., et al. Assessment of a HER2 scoring system for gastric cancer: results from a validation study. Histopathology 2008, 52(7):797-805.
29. Rüschoff J., Dietel M., Baretton G., et al. HER2 diagnostics in gastric cancer-guideline validation and development of standardized immunohistochemical testing. Virchows Arch 2010, 457(3):299-307.
30. Longacre T.A., Fenoglio-Preiser C.M. Mixed hyperplastic adenomatous polyps/serrated adenomas. A distinct form of colorectal neoplasia. Am J Surg Pathol 1990, 14(6):524-537.
31. Lu F.I., van Niekerk de W., Owen D., et al. Longitudinal outcome study of sessile serrated adenomas of the colorectum: an increased risk for subsequent right-sided colorectal carcinoma. Am J Surg Pathol 2010, 34(7):927-934.
32. Rex D.K., Ahnen D.J., Baron J.A., et al. Serrated lesions of the colorectum: review and recommendations from an expert panel. Am J Gastroenterol 2012, 107(9):1315-1329. [quiz: 4, 30].
33. Farris A.B., Misdraji J., Srivastava A., et al. Sessile serrated adenoma: challenging discrimination from other serrated colonic polyps. Am J Surg Pathol 2008, 32(1):30-35.
34. Owens S.R., Chiosea S.I., Kuan S.F. Selective expression of gastric mucin MUC6 in colonic sessile serrated adenoma but not in hyperplastic polyp aids in morphological diagnosis of serrated polyps. Mod Pathol 2008, 21(6):660-669.
35. Mochizuka A., Uehara T., Nakamura T., et al. Hyperplastic polyps and sessile serrated 'adenomas' of the colon and rectum display gastric pyloric differentiation. Histochem Cell Biol 2007, 128(5):445-455.
36. Bartley A.N., Thompson P.A., Buckmeier J.A., et al. Expression of gastric pyloric mucin, MUC6, in colorectal serrated polyps. Mod Pathol 2010, 23(2):169-176.
37. Fujita K., Hirahashi M., Yamamoto H., et al. Mucin core protein expression in serrated polyps of the large intestine. Virchows Arch 2010, 457(4):443-449.
38. Gibson J.A., Hahn H.P., Shahsafaei A., et al. MUC expression in hyperplastic and serrated colonic polyps: lack of specificity of MUC6. Am J Surg Pathol 2011, 35(5):742-749.
39. Huang C.C., Frankel W.L., Doukides T., et al. Prolapse-related changes are a confounding factor in misdiagnosis of sessile serrated adenomas in the rectum. Hum Pathol 2013, 44(4):480-486.
40. Bellizzi A.M., Frankel W.L. Colorectal cancer due to deficiency in DNA mismatch repair function: a review. Adv Anat Pathol 2009, 16(6):405-417.
41. Jenkins M.A., Hayashi S., O'Shea A.M., et al. Pathology features in Bethesda guidelines predict colorectal cancer microsatellite instability: a population-based study. Gastroenterology 2007, 133(1):48-56.
42. Greenson J.K., Huang S.C., Herron C., et al. Pathologic predictors of microsatellite instability in colorectal cancer. Am J Surg Pathol 2009, 33(1):126-133.
43. Hyde A., Fontaine D., Stuckless S., et al. Ahistology-based model for predicting microsatellite instability in colorectal cancers. Am J Surg Pathol 2010, 34(12):1820-1829.
44. Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group Recommendations from the EGAPP Working Group: genetic testing strategies in newly diagnosed individuals with colorectal cancer aimed at reducing morbidity and mortality from Lynch syndrome in relatives. Genet Med 2009, 11(1):35-41.
45. Funkhouser W.K., Lubin I.M., Monzon F.A., et al. Relevance, pathogenesis, and testing algorithm for mismatch repair-defective colorectal carcinomas: a report of the association for molecular pathology. JMol Diagn 2012, 14(2):91-103.
46. Sheridan T.B., Fenton H., Lewin M.R., et al. Sessile serrated adenomas with low- and high-grade dysplasia and early carcinomas: an immunohistochemical study of serrated lesions "caught in the act". Am J Clin Pathol 2006, 126(4):564-571.
47. Shia J., Stadler Z., Weiser M.R., et al. Immunohistochemical staining for DNA mismatch repair proteins in intestinal tract carcinoma: how reliable are biopsy samples?. Am J Surg Pathol 2011, 35(3):447-454.
48. Capper D., Voigt A., Bozukova G., et al. BRAF V600E-specific immunohistochemistry for the exclusion of Lynch syndrome in MSI-H colorectal cancer. Int J Cancer 2013, 133(7):1624-1630.
49. Affolter K., Samowitz W., Tripp S., et al. BRAF V600E mutation detection by immunohistochemistry in colorectal carcinoma. Genes Chromosomes Cancer 2013, 52(8):748-752.
50. Sinicrope F.A., Smyrk T.C., Tougeron D., et al. Mutation-specific antibody detects mutant BRAF protein expression in human colon carcinomas. Cancer 2013, 119(15):2765-2770.
51. Adackapara C.A., Sholl L.M., Barletta J.A., et al. Immunohistochemistry using a BRAF V600E mutation-specific monoclonal antibody is not a useful surrogate for genotyping in colorectal adenocarcinoma. Histopathology 2013, 63(2):187-193.
52. Kuan S.F., Pai R.K., Navina S., et al. Assessment of BRAF V600E mutation-specific antibody (VE1) in colorectal cancers. Mod Pathol 2013, 26(Suppl 2):161A.
53. Koperek O., Kornauth C., Capper D., et al. Immunohistochemical detection of the BRAF V600E-mutated protein in papillary thyroid carcinoma. Am J Surg Pathol 2012, 36(6):844-850.
54. Long G.V., Wilmott J.S., Capper D., et al. Immunohistochemistry is highly sensitive and specific for the detection of V600E BRAF mutation in melanoma. Am J Surg Pathol 2013, 37(1):61-65.
55. Zucman-Rossi J., Jeannot E., Nhieu J.T., et al. Genotype-phenotype correlation in hepatocellular adenoma: new classification and relationship with HCC. Hepatology 2006, 43(3):515-524.
56. Kong C.S., Appenzeller M., Ferrell L.D. Utility of CD34 reactivity in evaluating focal nodular hepatocellular lesions sampled by fine needle aspiration biopsy. Acta Cytol 2000, 44(2):218-222.
57. Yamauchi N., Watanabe A., Hishinuma M., et al. The glypican 3 oncofetal protein is a promising diagnostic marker for hepatocellular carcinoma. Mod Pathol 2005, 18(12):1591-1598.
58. Wang X.Y., Degos F., Dubois S., et al. Glypican-3 expression in hepatocellular tumors: diagnostic value for preneoplastic lesions and hepatocellular carcinomas. Hum Pathol 2006, 37(11):1435-1441.
59. Shafizadeh N., Ferrell L.D., Kakar S. Utility and limitations of glypican-3 expression for the diagnosis of hepatocellular carcinoma at both ends of the differentiation spectrum. Mod Pathol 2008, 21(8):1011-1018.
60. Wang H.L., Anatelli F., Zhai Q.J., et al. Glypican-3 as auseful diagnostic marker that distinguishes hepatocellular carcinoma from benign hepatocellular mass lesions. Arch Pathol Lab Med 2008, 132(11):1723-1728.
61. Tremosini S., Forner A., Boix L., et al. Prospective validation of an immunohistochemical panel (glypican 3, heat shock protein 70 and glutamine synthetase) in liver biopsies for diagnosis of very early hepatocellular carcinoma. Gut 2012, 61(10):1481-1487.
62. Bioulac-Sage P., Cubel G., Taouji S., et al. Immunohistochemical markers on needle biopsies are helpful for the diagnosis of focal nodular hyperplasia and hepatocellular adenoma subtypes. Am J Surg Pathol 2012, 36(11):1691-1699.
63. Rebouissou S., Couchy G., Libbrecht L., et al. The beta-catenin pathway is activated in focal nodular hyperplasia but not in cirrhotic FNH-like nodules. JHepatol 2008, 49(1):61-71.
64. Abdul-Al H.M., Makhlouf H.R., Wang G., et al. Glypican-3 expression in benign liver tissue with active hepatitis C: implications for the diagnosis of hepatocellular carcinoma. Hum Pathol 2008, 39(2):209-212.
65. Lagana S.M., Moreira R.K., Remotti H.E., et al. Glutamine synthetase, heat shock protein-70, and glypican-3 in intrahepatic cholangiocarcinoma and tumors metastatic to liver. Appl Immunohistochem Mol Morphol 2013, 21(3):254-257.
66. Kakar S., Gown A.M., Goodman Z.D., et al. Best practices in diagnostic immunohistochemistry: hepatocellular carcinoma versus metastatic neoplasms. Arch Pathol Lab Med 2007, 131(11):1648-1654.
67. Lau S.K., Prakash S., Geller S.A., et al. Comparative immunohistochemical profile of hepatocellular carcinoma, cholangiocarcinoma, and metastatic adenocarcinoma. Hum Pathol 2002, 33(12):1175-1181.
68. Sheahan K., O'Brien M.J., Burke B., et al. Differential reactivities of carcinoembryonic antigen (CEA) and CEA-related monoclonal and polyclonal antibodies in common epithelial malignancies. Am J Clin Pathol 1990, 94(2):157-164.
69. Butler S.L., Dong H., Cardona D., et al. The antigen for Hep Par 1 antibody is the urea cycle enzyme carbamoyl phosphate synthetase 1. Lab Invest 2008, 88(1):78-88.
70. Fan Z., van de Rijn M., Montgomery K., et al. Hep par 1 antibody stain for the differential diagnosis of hepatocellular carcinoma: 676 tumors tested using tissue microarrays and conventional tissue sections. Mod Pathol 2003, 16(2):137-144.
71. Lugli A., Tornillo L., Mirlacher M., et al. Hepatocyte paraffin 1 expression in human normal and neoplastic tissues: tissue microarray analysis on 3,940 tissue samples. Am J Clin Pathol 2004, 122(5):721-727.
72. Baumhoer D., Tornillo L., Stadlmann S., et al. Glypican 3 expression in human nonneoplastic, preneoplastic, and neoplastic tissues: a tissue microarray analysis of 4,387 tissue samples. Am J Clin Pathol 2008, 129(6):899-906.
73. Mounajjed T., Zhang L., Wu T.T. Glypican-3 expression in gastrointestinal and pancreatic epithelial neoplasms. Hum Pathol 2013, 44(4):542-550.
74. Yan B.C., Gong C., Song J., et al. Arginase-1: a new immunohistochemical marker of hepatocytes and hepatocellular neoplasms. Am J Surg Pathol 2010, 34(8):1147-1154.
75. Abraham S.C., Klimstra D.S., Wilentz R.E., et al. Solid-pseudopapillary tumors of the pancreas are genetically distinct from pancreatic ductal adenocarcinomas and almost always harbor beta-catenin mutations. Am J Pathol 2002, 160(4):1361-1369.
76. La Rosa S., Adsay V., Albarello L., et al. Clinicopathologic study of 62 acinar cell carcinomas of the pancreas: insights into the morphology and immunophenotype and search for prognostic markers. Am J Surg Pathol 2012, 36(12):1782-1795.
77. Tanaka Y., Kato K., Notohara K., et al. Significance of aberrant (cytoplasmic/nuclear) expression of beta-catenin in pancreatoblastoma. JPathol 2003, 199(2):185-190.
78. Chetty R., Serra S. Membrane loss and aberrant nuclear localization of E-cadherin are consistent features of solid pseudopapillary tumour of the pancreas. An immunohistochemical study using two antibodies recognizing different domains of the E-cadherin molecule. Histopathology 2008, 52(3):325-330.
79. Yao J.C., Hassan M., Phan A., et al. One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. JClin Oncol 2008, 26(18):3063-3072.
80. Savelli G., Lucignani G., Seregni E., et al. Feasibility of somatostatin receptor scintigraphy in the detection of occult primary gastro-entero-pancreatic (GEP) neuroendocrine tumours. Nucl Med Commun 2004, 25(5):445-449.
81. Lorenzo P.I., Jimenez Moreno C.M., Delgado I., et al. Immunohistochemical assessment of Pax8 expression during pancreatic islet development and in human neuroendocrine tumors. Histochem Cell Biol 2011, 136(5):595-607.
82. Graham R.P., Shrestha B., Caron B.L., et al. Islet-1 is a sensitive but not entirely specific marker for pancreatic neuroendocrine neoplasms and their metastases. Am J Surg Pathol 2013, 37(3):399-405.
83. Chan E.S., Alexander J., Swanson P.E., et al. PDX-1, CDX-2, TTF-1, and CK7: a reliable immunohistochemical panel for pancreatic neuroendocrine neoplasms. Am J Surg Pathol 2012, 36(5):737-743.
84. Srivastava A., Hornick J.L. Immunohistochemical staining for CDX-2, PDX-1, NESP-55, and TTF-1 can help distinguish gastrointestinal carcinoid tumors from pancreatic endocrine and pulmonary carcinoid tumors. Am J Surg Pathol 2009, 33(4):626-632.
85. Lugli A., Tzankov A., Zlobec I., et al. Differential diagnostic and functional role of the multi-marker phenotype CDX2/CK20/CK7 in colorectal cancer stratified by mismatch repair status. Mod Pathol 2008, 21(11):1403-1412.
86. Winn B., Tavares R., Fanion J., et al. Differentiating the undifferentiated: immunohistochemical profile of medullary carcinoma of the colon with an emphasis on intestinal differentiation. Hum Pathol 2009, 40(3):398-404.
87. Saad R.S., Silverman J.F., Khalifa M.A., et al. CDX2, cytokeratins 7 and 20 immunoreactivity in rectal adenocarcinoma. Appl Immunohistochem Mol Morphol 2009, 17(3):196-201.
88. Logani S., Oliva E., Arnell P.M., et al. Use of novel immunohistochemical markers expressed in colonic adenocarcinoma to distinguish primary ovarian tumors from metastatic colorectal carcinoma. Mod Pathol 2005, 18(1):19-25.
89. Wang H.L., Lu D.W., Yerian L.M., et al. Immunohistochemical distinction between primary adenocarcinoma of the bladder and secondary colorectal adenocarcinoma. Am J Surg Pathol 2001, 25(11):1380-1387.
90. Suh N., Yang X.J., Tretiakova M.S., et al. Value of CDX2, villin, and alpha-methylacyl coenzyme A racemase immunostains in the distinction between primary adenocarcinoma of the bladder and secondary colorectal adenocarcinoma. Mod Pathol 2005, 18(9):1217-1222.
91. Vang R., Gown A.M., Barry T.S., et al. Cytokeratins 7 and 20 in primary and secondary mucinous tumors of the ovary: analysis of coordinate immunohistochemical expression profiles and staining distribution in 179 cases. Am J Surg Pathol 2006, 30(9):1130-1139.
92. Nonaka D., Kusamura S., Baratti D., et al. CDX-2 expression in pseudomyxoma peritonei: a clinicopathological study of 42 cases. Histopathology 2006, 49(4):381-387.
93. Yemelyanova A.V., Vang R., Judson K., et al. Distinction of primary and metastatic mucinous tumors involving the ovary: analysis of size and laterality data by primary site with reevaluation of an algorithm for tumor classification. Am J Surg Pathol 2008, 32(1):128-138.
94. Goldstein N.S., Bassi D. Cytokeratins 7, 17, and 20 reactivity in pancreatic and ampulla of vater adenocarcinomas. Percentage of positivity and distribution is affected by the cut-point threshold. Am J Clin Pathol 2001, 115(5):695-702.
95. Chu P.G., Schwarz R.E., Lau S.K., et al. Immunohistochemical staining in the diagnosis of pancreatobiliary and ampulla of Vater adenocarcinoma: application of CDX2, CK17, MUC1, and MUC2. Am J Surg Pathol 2005, 29(3):359-367.
96. Ji H., Isacson C., Seidman J.D., et al. Cytokeratins 7 and 20, Dpc4, and MUC5AC in the distinction of metastatic mucinous carcinomas in the ovary from primary ovarian mucinous tumors: Dpc4 assists in identifying metastatic pancreatic carcinomas. Int J Gynecol Pathol 2002, 21(4):391-400.
97. Wang N.P., Zee S., Zarbo R.J., et al. Coordinate expression of cytokeratins 7 and 20 defined unique subsets of carcinomas. Appl Immunohistochem 1995, 3(2):99-107.
98. Chu P., Wu E., Weiss L.M. Cytokeratin 7 and cytokeratin 20 expression in epithelial neoplasms: a survey of 435 cases. Mod Pathol 2000, 13(9):962-972.
99. Taniere P., Borghi-Scoazec G., Saurin J.C., et al. Cytokeratin expression in adenocarcinomas of the esophagogastric junction: a comparative study of adenocarcinomas of the distal esophagus and of the proximal stomach. Am J Surg Pathol 2002, 26(9):1213-1221.
100. Chen Z.M., Wang H.L. Alteration of cytokeratin 7 and cytokeratin 20 expression profile is uniquely associated with tumorigenesis of primary adenocarcinoma of the small intestine. Am J Surg Pathol 2004, 28(10):1352-1359.
101. Magnusson K., de Wit M., Brennan D.J., et al. SATB2 in combination with cytokeratin 20 identifies over 95% of all colorectal carcinomas. Am J Surg Pathol 2011, 35(7):937-948.